Cargando…

Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?

BACKGROUND: Following neoadjuvant chemotherapy (NACT) for breast cancer, changes in estrogen receptor (ER), progesterone receptor (PR), HER2 status, and Ki-67 index (IHC4 status) and its correlation with pathological complete response (pCR) or relapse-free survival (RFS) rates could lead to better u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatterjee, Sanjoy, Saha, Animesh, Arun, Indu, Nayak, Sonali Susmita, Sinha, Subir, Agrawal, Sanjit, Parihar, Mayur, Ahmed, Rosina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677657/ https://www.ncbi.nlm.nih.gov/pubmed/26677343 http://dx.doi.org/10.2147/BCTT.S94516

Ejemplares similares

Oncologic safety of breast conservation following NACT in women with locally advanced breast cancer
por: Agrawal, Sanjit Kumar, et al.
Publicado: (2023)

The NACT Training Package
por: Scarpello, John H. B.
Publicado: (1991)

L-Arginine and Cardioactive Arginine Derivatives as Substrates and Inhibitors of Human and Mouse NaCT/Nact
por: Surrer, Daniela B., et al.
Publicado: (2022)

NACT+IMRT versus NACT+IMRT+CCRT in locoregionally advanced NPC patients: a retrospective study
por: Chen, Xialin, et al.
Publicado: (2019)

Structure and inhibition mechanism of the human citrate transporter NaCT
por: Sauer, David B., et al.
Publicado: (2021)

The Role of GOLPH3L in the Prognosis and NACT response in Cervical Cancer
por: Feng, Yanling, et al.
Publicado: (2017)

Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT
por: Zhu, Haiyan, et al.
Publicado: (2019)

Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands
por: Miquel-Cases, Anna, et al.
Publicado: (2016)

Model‐Based Assessment of Plasma Citrate Flux Into the Liver: Implications for NaCT as a Therapeutic Target
por: Li, Z, et al.
Publicado: (2016)

Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)
por: Huard, Kim, et al.
Publicado: (2015)

NaCT/SLC13A5 facilitates citrate import and metabolism under nutrient-limited conditions
por: Kumar, Avi, et al.
Publicado: (2021)

“This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients”
por: Galimberti, Viviana, et al.
Publicado: (2022)

Molecular Subtypes As Emerging Predictors of Clinicopathological Response to Neoadjuvant Chemotherapy (NACT) in Locally Advanced Breast Cancer (LABC): A Single-Centre Experience in Western India
por: Sharma, Sarthak, et al.
Publicado: (2022)

Analysis of naturally occurring mutations in the human uptake transporter NaCT important for bone and brain development and energy metabolism
por: Selch, Stefan, et al.
Publicado: (2018)

The Hepatic Plasma Membrane Citrate Transporter NaCT (SLC13A5) as a Molecular Target for Metformin
por: Kopel, Jonathan, et al.
Publicado: (2020)

The sodium-dependent di- and tricarboxylate transporter, NaCT, is not responsible for the uptake of D-, L-2-hydroxyglutarate and 3-hydroxyglutarate into neurons
por: Brauburger, Katja, et al.
Publicado: (2011)

BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC)
por: Glynne-Jones, R., et al.
Publicado: (2018)

A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity
por: Zahn, Grit, et al.
Publicado: (2022)

Consequences of NaCT/SLC13A5/mINDY deficiency: good versus evil, separated only by the blood–brain barrier
por: Kopel, Jonathan J., et al.
Publicado: (2021)

Functional analysis of a species-specific inhibitor selective for human Na(+)-coupled citrate transporter (NaCT/SLC13A5/mINDY)
por: Higuchi, Kei, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC)
por: Kashyap1, Lakhan, et al.
Publicado: (2021)

Immunohistochemistry Heterogeneity in Reported Breast Cancer Demographics From India: Triple-Negative Breast Cancer Rates Could Be Lower Than Suggested in Pooled Meta-Analysis
por: Chatterjee, Sanjoy, et al.
Publicado: (2016)

Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis
por: Kolberg, Hans-Christian, et al.
Publicado: (2020)

Correction: Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis
por: Kolberg, Hans-Christian, et al.
Publicado: (2020)

Clinicopathological characteristics and prognostic analysis of breast cancer with a hormone receptor status of ER(-)/PR(+)
por: Wang, Xinli, et al.
Publicado: (2023)

The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis
por: Swarnkar, Parinita K., et al.
Publicado: (2021)

A home run for human NaCT/SLC13A5/INDY: cryo-EM structure and homology model to predict transport mechanisms, inhibitor interactions and mutational defects
por: Jaramillo-Martinez, Valeria, et al.
Publicado: (2021)

Allred Scoring of ER-IHC Stained Whole-Slide Images for Hormone Receptor Status in Breast Carcinoma
por: Ahmad Fauzi, Mohammad Faizal, et al.
Publicado: (2022)

Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
por: Garziera, Marica, et al.
Publicado: (2019)

Stigma Perceived by Women Following Surgery for Breast Cancer
por: Tripathi, Lopamudra, et al.
Publicado: (2017)

Microsatellite Status Detection of Colorectal Cancer: Evaluation of Inconsistency between PCR and IHC
por: Chen, Jielin, et al.
Publicado: (2023)

Effect of non-sentinel metastasis on adjuvant treatment decisions and survival in Z0011 eligible non-screened detected breast cancer population
por: Agrawal, Sanjit Kumar, et al.
Publicado: (2021)

How do clinicians rate patient’s performance status using the ECOG performance scale? A mixed-methods exploration of variability in decision-making in oncology
por: Datta, Soumitra S, et al.
Publicado: (2019)

P62/Ubiquitin IHC Expression Correlated with Clinicopathologic Parameters and Outcome in Gastrointestinal Carcinomas
por: Mohamed, Amr, et al.
Publicado: (2015)

The expression status of TRX, AR, and cyclin D1 correlates with clinicopathological characteristics and ER status in breast cancer
por: Huang, Weisun, et al.
Publicado: (2016)

An Advanced Deep Learning Approach for Ki-67 Stained Hotspot Detection and Proliferation Rate Scoring for Prognostic Evaluation of Breast Cancer
por: Saha, Monjoy, et al.
Publicado: (2017)

Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer
por: Sui, Weiguo, et al.
Publicado: (2009)

ALK-Rearranged Lung Cancer in Chinese: A Comprehensive Assessment of Clinicopathology, IHC, FISH and RT-PCR
por: Li, Yuan, et al.
Publicado: (2013)

Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques
por: Nedjadi, Taoufik, et al.
Publicado: (2016)

Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features
por: Cao, Bing, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u5ghb9vv5g10qrsck2etmqeu3q